Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: Is there is a place for obstructive sleep apnea?

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Mirrakhimov, Aibek E ^a  

^a Kyrgyz State Medical Academy   (Kyrgyzstan)

Author keywords

Cardiometabolic risk; Non alcoholic fatty liver disease; Non alcoholic fatty pancreatic disease; Obstructive sleep apnea; Pancreatic cancer; Pancreatitis

Indexed keywords

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; PANCREATITIS; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84893171156     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-29     Document Type: Article

References (57)

1. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task force. Sleep 1999, 22:667-689.
2. Mannarino MR, Di Filippo F, Pirro M. Obstructive sleep apnea syndrome. Eur J Intern Med 2012, 23:586-593. 10.1016/j.ejim.2012.05.013, 22939801.
3. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235. 10.1056/NEJM199304293281704, 8464434.
4. Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link?. Front Neurol 2012, 3:126. 3449487, 23015803.
5. Mirrakhimov AE, Polotsky VY. Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?. Front Neurol 2012, 3:149. 3473309, 23087670.
6. Baguet JP, Barone-Rochette G, Tamisier R, Levy P, Pépin JL. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol 2012, 9:679-688. 10.1038/nrcardio.2012.141, 23007221.
7. Mirrakhimov AE. Supine fluid redistribution: should we consider this as an important risk factor for obstructive sleep apnea?. Sleep Breath 2013, 17:511-523. 10.1007/s11325-012-0755-6, 22872284.
8. Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farré R. Sleep-disordered breathing and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care Med 2012, 186:190-194. 10.1164/rccm.201201-0130OC, 3406081, 22610391.
9. Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, Duran-Cantolla J, Peña Mde L, Masdeu MJ, Gonzalez M, Campo F, Gallego I, Marin JM, Barbe F, Montserrat JM, Farre R. Association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med 2013, 187:99-105. 10.1164/rccm.201209-1671OC, 23155146.
10. Zhang X, Giovannucci EL, Wu K, Gao X, Hu F, Ogino S, Schernhammer ES, Fuchs CS, Redline S, Willett WC, Ma J. Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. Sleep 2013, 36:681-688. 3624822, 23633750.
11. Mirrakhimov AE, Barbaryan A. Obstructive sleep apnea and cancer: is it time to study organ-specific cancers?. Am J Respir Crit Care Med 2013, 188:399.
12. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012, 33:1190-1200. 10.1093/eurheartj/ehr453, 22408036.
13. Pacana T, Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis 2012, 16:599-613. 10.1016/j.cld.2012.05.008, 22824483.
14. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012, 9:372-381. 10.1038/nrgastro.2012.79, 22565095.
15. Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med 2012, 29:1098-1107. 10.1111/j.1464-5491.2012.03732.x, 22672330.
16. Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol 2012, 11:61. 10.1186/1475-2840-11-61, 3471007, 22676459.
17. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.e2. 3501546, 23041539.
18. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013, 14:417-431. 10.1111/obr.12020, 23387384.
19. Minville C, Hilleret MN, Tamisier R, Aron-Wisnewsky J, Clement K, Trocme C, Borel JC, Levy P, Zarski JP, Pepin JL. Nonalcoholic fatty liver disease, nocturnal hypoxia and endothelial function in sleep apnea patients. Chest 2013, Nov 21. doi:10.1378/chest.13-0938. [Epub ahead of print].
20. Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013, 23:1815-1825. 10.1007/s11695-013-0981-4, 23740153.
21. Wu WC, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol 2013, 12:77. 10.1186/1475-2840-12-77, 3682938, 23688357.
22. Lee JS, Kim SH, Jun DW, Han JH, Jang EC, Park JY, Son BK, Kim SH, Jo YJ, Park YS, Kim YS. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 2009, 15:1869-1875. 10.3748/wjg.15.1869, 2670415, 19370785.
23. Martínez J, Johnson CD, Sánchez-Payá J, de Madaria E, Robles-Díaz G, Pérez-Mateo M. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006, 6:206-209. 10.1159/000092104, 16549939.
24. Sepe PS, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G, Mehta G, Chuttani R, Kane R, Pleskow D, Sawhney MS. A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc 2011, 73:987-993. 10.1016/j.gie.2011.01.015, 21521567.
25. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286(8):921-929. 10.1001/jama.286.8.921, 11509056.
26. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009, 301:2553-2562. 10.1001/jama.2009.886, 2760963, 19549972.
27. Thiébaut AC, Jiao L, Silverman DT, Cross AJ, Thompson FE, Subar AF, Hollenbeck AR, Schatzkin A, Stolzenberg-Solomon RZ. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst 2009, 101:1001-1011. 10.1093/jnci/djp168, 2724851, 19561318.
28. Pallayova M, Lazurova I, Donic V. Hypoxic damage to pancreatic beta cells-the hidden link between sleep apnea and diabetes. Med Hypotheses 2011, 77:930-934. 10.1016/j.mehy.2011.08.016, 21899957.
29. Mirrakhimov AE, Ali AM. Pathobiology of obstructive sleep apnea-related dyslipidemia: focus on the liver. ISRN Cardiol 2013, 2013:687069. 3549373, 23346414.
30. Adedayo AM, Olafiranye O, Smith D, Hill A, Zizi F, Brown C, Jean-Louis G. Obstructive sleep apnea and dyslipidemia: evidence and underlying mechanism. Sleep Breath 2012, Aug 18. [Epub ahead of print].
31. Drager LF, Jun JC, Polotsky VY. Metabolic consequences of intermittent hypoxia: relevance to obstructive sleep apnea. Best Pract Res Clin Endocrinol Metab 2010, 24:843-851. 10.1016/j.beem.2010.08.011, 3011976, 21112030.
32. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009, 24:97-106. 10.1152/physiol.00045.2008, 19364912.
33. Semenza GL. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 2009, 15:3839-3843. 10.2174/138161209789649402, 19671047.
34. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010, 20:51-56. 10.1016/j.gde.2009.10.009, 2822127, 19942427.
35. Semenza GL. Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology. Annu Rev Pathol 2013, Aug 7. [Epub ahead of print].
36. Schaefer JH. The normal weight of the pancreas in the adult human being: A biometric study. Anat Rec 1926, 32:119-132.
37. Ogilvie RF. The islands of Langerhans in 19 cases of obesity. J Pathol Bacteriol 1933, 37:473-481.
38. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998, 95:2498-2502. 10.1073/pnas.95.5.2498, 19389, 9482914.
39. Mathur A, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA. Nonalcoholic fatty pancreas disease. HPB (Oxford) 2007, 9:312-318. 10.1080/13651820701504157, 2215403, 18345311.
40. Lee Y, Lingvay I, Szczepaniak LS, Ravazzola M, Orci L, Unger RH. Pancreatic steatosis: harbinger of type 2 diabetes in obese rodents. Int J Obes (Lond) 2010, 34:396-400. 10.1038/ijo.2009.245, 20010902.
41. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007, 30:2916-2921. 10.2337/dc07-0326, 17666465.
42. Walters MN. Adipose atrophy of the exocrine pancreas. J Pathol Bacteriol 1966, 92:547-557. 10.1002/path.1700920232, 5964381.
43. Olsen TS. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol Microbiol Scand A 1978, 86A:367-373.
44. Al-Haddad M, Khashab M, Zyromski N, Pungpapong S, Wallace MB, Scolapio J, Woodward T, Noh K, Raimondo M. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. Pancreas 2009, 38:672-675. 10.1097/MPA.0b013e3181a9d5af, 19506531.
45. Choi CW, Kim GH, Kang DH, Kim HW, Kim DU, Heo J, Song GA, Park do Y, Kim S. Associated factors for a hyperechogenic pancreas on endoscopic ultrasound. World J Gastroenterol 2010, 16:4329-4334. 10.3748/wjg.v16.i34.4329, 2937114, 20818817.
46. Lingvay I, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS. Noninvasive quantification of pancreatic fat in humans. J Clin Endocrinol Metab 2009, 94:4070-4076. 10.1210/jc.2009-0584, 2758729, 19773401.
47. Rossi AP, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M, Di Francesco V, Barillari M, Pozzi Mucelli R, Zamboni M. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. Obesity (Silver Spring) 2011, 19:1747-1754. 10.1038/oby.2011.114, 21593811.
48. Lê KA, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M, Hu HH, Nayak KS, Goran MI. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care 2011, 34:485-490. 10.2337/dc10-0760, 3024373, 21270204.
49. Schwenzer NF, Machann J, Martirosian P, Stefan N, Schraml C, Fritsche A, Claussen CD, Schick F. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. Invest Radiol 2008, 43:330-337. 10.1097/RLI.0b013e31816a88c6, 18424954.
50. Sijens PE, Edens MA, Bakker SJ, Stolk RP. MRI-determined fat content of human liver, pancreas and kidney. World J Gastroenterol 2010, 16:1993-1998. 10.3748/wjg.v16.i16.1993, 2860076, 20419836.
51. Katz DS, Hines J, Math KR, Nardi PM, Mindelzun RE, Lane MJ. Using CT to reveal fat-containing abnormalities of the pancreas. AJR Am J Roentgenol 1999, 172:393-396. 10.2214/ajr.172.2.9930790, 9930790.
52. Hannukainen JC, Borra R, Linderborg K, Kallio H, Kiss J, Lepomäki V, Kalliokoski KK, Kujala UM, Kaprio J, Heinonen OJ, Komu M, Parkkola R, Ahotupa M, Lehtimäki T, Huupponen R, Iozzo P, Nuutila P. Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. J Hepatol 2011, 54:545-552. 10.1016/j.jhep.2010.07.029, 21112658.
53. van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 2010, 39:1185-1190. 10.1097/MPA.0b013e3181f6fce2, 20871475.
54. Heni M, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, Claussen CD, Stefan N, Häring HU, Fritsche A. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes Metab Res Rev 2010, 26:200-205. 10.1002/dmrr.1073, 20225188.
55. van der Zijl NJ, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ, Blaak EE, Diamant M. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011, 96:459-467. 10.1210/jc.2010-1722, 21084401.
56. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract 2013, 2013:498296. 3855930, 24348536.
57. Ou HY, Wang CY, Yang YC, Chen MF, Chang CJ. The association between nonalcoholic fatty pancreas disease and diabetes. PLoS One 2013, 8:8:e62561.